Hiroshi Azuma became President of Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) in April of 2022.  He has more than 30 years of experience in the pharmaceutical sector. Many of those years were at Mitsubishi Tanabe Pharma Corporation (MTPC), where he has held senior management positions in the Research Lab, Clinical Development, Data Science, Quality Assurance and Global Development.  He also served as Head of Planning and Coordination and Data Science at MTDA.  He most recently served as Vice President & Head of the Research Coordination Department (Sohyaku Management) at MTPC.

For more than 18 years, Ming has worked in clinical development and drug safety for pharmaceutical companies such as Wyeth, Amgen, TAP, and AbbVie. He has strong, diverse, global safety expertise and experience, encompassing Phase I trials, complete Life Cycle Management, and leadership of multiple product safety teams. Over the past two decades, Ming has published extensively in highly respected journals.

Hiroyuki Yamada joined Mitsubishi Tanabe Pharma Development America, Inc. in April 2018 as Director of  Production Technology & Supply Chain Department from its parent company, Mitsubishi Tanabe Pharma Corporation (MTPC).  In October 2019, he went back to MTPC as Vice President and Head of the Analytical Research Department. In August 2021, he returned to MTDA as Vice President and Head of the Production Technology & Supply Chain Department, responsible for the strengthening of global CMC (Chemistry Manufacturing & Control) development and the supply chain function.  He also directs all global CMC project teams from early development stage through launch.

Hiroyuki has more than 25 years of experience in CMC development, including 2 years at the University of Minnesota learning the advanced analytical techniques for the characterization of the pharmaceutical drugs.  More recently, he led the Production team for edaravone (Radicava®) launch in US.

A native from Colombia, Mauricio brings twenty-seven years of experience in pharmaceutical and biotech Companies in clinical research project management and operations.  Mauricio has worked in many therapeutic areas, including infectious disease, virology, immunology, oncology, inflammation, and CNS. He previously served as Vice President and Global Head of Clinical Operations & Program Management at ReViral. Prior to that he was Vice President of Program Management & Clinical Operations at Chimerix where he was also involved in a long- standing collaboration with BARDA. He has also held leadership positions at EMD Serono, Vertex, Eli Lilly and Glaxo SmithKline.  Mauricio holds a doctorate in immunology from the University of Stockholm, Sweden and has published over 20 peer reviewed articles.

In her role as Head of Human Resources (HR), Deborah Moorer oversees the strategic direction of all aspects of HR and is instrumental in shaping the company’s culture and employee development. She brings more than 20 years of HR experience to the role. Prior to joining Mitsubishi Tanabe Pharma Development America, Inc., she was Vice President of HR at Ipsen Biopharmaceuticals, Senior Vice President and HR Advisor at Citibank, and Vice President of HR at Alpharma.

Encompassing the Neuroscience TA, Immunology TA, and the Translational Medicine group, Hernan leads an organization of clinical scientists focused on advancing innovation in the pipeline of Mitsubishi-Tanabe at a global level. Hernan, a psychiatrist by training with 8 years of clinical practice and academic research, brings a wealth of experience in the design and implementation of  phase I to phase IV clinical trials, in neuroscience (ie, depression, schizophrenia, anxiety, neuropathic pain, Alzheimer’s disease) and Immunology (psoriathic disease, Behcet’s disease, IBD). Before joining Mitsubishi-Tanabe Hernan was Vice President of Medical Science at Alector (a biotech specialised in neuro-immunitary pathways in neurodegeneration) and held positions of growing responsibility in clinical development at Eli Lilly and Amgen. Hernan holds a PhD in neuroscience by the Sorbonne University of Paris, France, and has authored over 50 publications in peer-reviewed medical journals.

As Global Head of Sourcing, Anthony Fuller is responsible for all aspects of Mitsubishi Tanabe’s work with external suppliers and service providers.  He leads the company’s sustainable procurement and supply risk management activities, oversees governance and partnership models, and develops long-term strategies to create shared value through collaboration with supplier ecosystems.

Anthony is a Fellow of the Chartered Institute of Procurement and Supply, a Certified Professional in Supply Management, a graduate of the universities of Oxford, Sheffield and Northumbria, and an alumnus of the Cambridge Institute for Sustainability Leadership.  He brings 25 years of experience in the industry, having started his pharma career at Roche; prior to joining Mitsubishi Tanabe in 2013 he held sourcing roles at Lilly and BMS.  He has also served in numerous leadership and elected positions in professional associations such as CIPS, World Commerce and Contracting, and the Sustainable Procurement Pledge.

Patrick Guinn leads the implementation of inciteful global regulatory strategies based on an in-depth working knowledge of the ever-changing regulatory landscape for global development programs, which has evolved throughout his 25+ years of scientific, pharmaceutical, and leadership experience. He has been directly involved in obtaining approvals for products in oncology, cardiology, pulmonary, neurology, psychiatry, inflammation, pain, dermatology, pediatrics, and rare diseases, as well as ensuring that patients have access to safe and effective products. His diverse career and experience includes more than 10 years at several Japanese pharmaceutical companies; 6 years as a Consultant developing global regulatory strategy plans for multiple pharmaceutical companies; 10 years working at the Food and Drug Administration (FDA) as a Regulatory Health Project Manager in the Center for Drug Evaluation and Research (CDER) Executive Operations Staff, CDER Office of Drug Safety, CDER Division of Oncology Drug Products, and as a Policy Analyst (brief detail in 2001) in the FDA Office of the Commissioner developing the FDA 5 Year Plan; and 3 years at the National Institutes of Health (NIH).